Lilly Asia Ventures VC
Investments by market, targeted sectors and preferred funding rounds
Name - Lilly Asia Ventures
Description - Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Investor Type - VC
Preferred rounds -
Location - Shanghai,
Investments by industry
biotech - 80%
B2B software - 20%
Number of investments: 5
Lilly Asia Ventures invested in Regor Therapeutics during a round worth $90,000,000 - 2/19/2021
Lilly Asia Ventures invested in dMed during a round worth $100,000,000 - 12/17/2020
Lilly Asia Ventures invested in Eluminex Biosciences during a round worth $50,000,000 - 11/30/2020
Lilly Asia Ventures invested in CARsgen Therapeutics during a round worth D186,000,000 - 11/3/2020
Lilly Asia Ventures invested in Gracell Biotechnologies during a round worth $100,000,000 - 10/29/2020